Clinical trials: Non Organic Psychosis
Alzheimer's Disease
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
- Trial name
- NCT05227118
- Testing
- Elpipodect
- Where
- 8 sites in United States
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Early Psychosis, Psychosis
State Representation in Early Psychosis 2
This observational study will examine behavioral and electroencephalography measures related to state representation in individuals with early psychosis and healthy control participants.
- Conditions
- Early Psychosis, Psychosis, Schizophrenia, Bipolar Disorder With Psychosis
- Trial name
- STEP2 (NCT07834203)
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Methamphetamine Dependence
An Study of Aripiprazole in the Treatment of Methamphetamine Dependence
Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics，but have different pharmacological effects of…
- Trial name
- NCT01813656
- Testing
- Aripiprazole
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Wei Hao
First Episode Psychosis, Psychosis
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
Psychosis is a disabling condition that typically has its onset in adolescence and early adulthood. Many young people with psychosis have difficulty navigating services or are reluctant to engage in treatment until their illness…
- Conditions
- First Episode Psychosis, Psychosis, Psychotic Episode, Psychoses, Affective
- Trial name
- NCT04298450
- Testing
- Active SMS Intervention
- Where
- Canada
- Volunteers
- 186 people
- Sponsor
- Centre for Addiction and Mental Health
Individuals at Risk of First Episode Psychosis
Culturally Adapted Cognitive Behavior Therapy for Individuals At Risk of First Episode Psychosis
Young people constitute nearly half of Pakistan's population and are highly vulnerable to risk factors for mental illness, including poverty, inequality, abuse, and violence.
- Trial name
- NCT07188597
- Testing
- Cognitive Behavior Therapy for those at risk of first episode psychosis
- Where
- 2 sites in Pakistan
- Volunteers
- 90 people
- Sponsor
- Pakistan Institute of Living and Learning
Psychosis
Mindfulness, Group Therapy and Psychosis; Training Decreases Anxiety and Depression
The objective of this non-randomized, within-group comparison was to evaluate the addition of mindfulness as a new technique in an outpatient group therapy program for participants diagnosed with a psychotic spectrum disorder…
- Trial name
- NCT04711460
- Testing
- Younger participants, Older participants, TAU
- Volunteers
- 116 people
- Sponsor
- University of Minnesota
Metabolic Syndrome, Mental Disorders
Impact of Aerobic Exercise on Metabolic Syndrome, Neurocognition and Empowerment in Individuals With Mental Disorders
This study aims to develop a program of systematic physical exercise maintained for at least 12 weeks to normalize biomarkers of metabolic syndrome; improve neurocognition and social functioning; increase empowerment, self-esteem…
- Trial name
- EXERTMG (NCT02858102)
- Testing
- Physical activity program
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundación Marques de Valdecilla
Parkinson Disease
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD.
- Trial name
- NCT03582137
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Psychosis
USS Training to Improve Social Function in People With Psychosis
Psychotic spectrum disorders (PSD) are associated with poor social function. By doing this study, the investigators hope to learn which of two different types of 2-month long training courses is more effective in improving…
- Trial name
- NCT04557124
- Testing
- USS, MovingForward
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizophrenia; Psychosis
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and…
- Trial name
- NCT04659161
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 22 sites in United States
- Volunteers
- 252 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Auditory Hallucination, Hearing Voices When No One is Talking
Imagery Interventions for Auditory Vocal Hallucinations
This study explores the feasibility, acceptability, and effectiveness of four imagery intervention techniques (metacognitive imagery intervention, imagery rescripting, promoting positive imagery and competing imagery task) for…
- Conditions
- Auditory Hallucination, Hearing Voices When No One is Talking, Psychosis
- Trial name
- NCT05603260
- Testing
- Imagery intervention for voice hearing (meta-cognitive imagery rescripting), Imagery intervention for voice hearing (Imagery rescripting), Imagery intervention for voice hearing (promoting positive imagery de novo)
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Hella Janssen
Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis
Stratification and Treatment in Early Psychosis Study - PROMOTE
The purpose of this trial is: To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
- Conditions
- Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
- Trial name
- STEP-PROMOTE (NCT07434973)
- Testing
- Cannabidiol (CBD)
- Where
- 19 sites in Austria, Canada and 8 more
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Psychosis, Clinical High Risk for Psychosis
Using Mobile Technology to Enhance Early Psychosis Treatment Delivery
This project tests the feasibility of implementing a smartphone application - Ginger.io - in the UC Davis Early Psychosis Program, and investigates whether mobile health technology can improve treatment delivery and outcomes in…
- Trial name
- RWJFGinger (NCT03303456)
- Testing
- Mobile health application - Ginger.io
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Device Adherence
Effectiveness of a Digital Platform in Engagement and Prognosis of Patients in an Early Intervention Pychosis Programme
This is a randomised, prospective, controlled trial in which one group (experimental group; GE) receives access to the PIPPEP (Intervention Programme for Early Psychosis) platform in addition to the treatment as usual (TAU) in…
- Trial name
- NCT06556251
- Testing
- PIPPEP App
- Where
- Spain
- Volunteers
- 128 people
- Sponsor
- Fundació Sant Joan de Déu
Prodromal Schizophrenia
Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk
This study will investigate whether a single dose of diazepam (5mg) compared to placebo can modulate brain chemistry (GABA/glutamate levels) and function (blood flow, neural response and connectivity during tasks and at-rest) in…
- Trial name
- BENZOGAP (NCT06190483)
- Testing
- Diazepam 5 Mg Oral Tablet, Ascorbic Acid 50 Mg Oral Tablet
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- King's College London
Schizophrenia, Schizoaffective Disorder
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Multifamily group psychoeducation [MFG] and group cognitive behavioral therapy [GCBT] are evidence-based treatments for first episode psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features
- Trial name
- NCT01570972
- Testing
- Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of Arizona
Psychotic Disorders, Recent-Onset Psychosis
Effects of a Peer-facilitated, Acceptance-based Self-learning for Illness Management (PASIM) Program
Psychosis is a very disabling mental illness with a wide range of dysregulations and disruptions in cognition, emotions, and behaviors, resulting in poor functioning and frequent relapses, especially in the first five years of…
- Trial name
- NCT07129369
- Testing
- PASIM program, Psychoeducation, Usual-Care-only
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- Chinese University of Hong Kong
Psychotic Disorder
Speech-based Assessment of Relapse Risk in People With Psychosis
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis.
- Trial name
- TRUSTING-WP4 (NCT07397975)
- Testing
- Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
- Where
- 7 sites in Czechia, Ireland and 4 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Philipp Homan
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
- Trial name
- NCT06068465
- Testing
- pimavanserin tartrate
- Where
- 60 sites in China
- Volunteers
- 248 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.